Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy
Heat-shock protein 90 (HSP90) is an important molecule chaperone associated with tumorigenesis and malignancy. HSP90 is involved in the folding and maturation of a wide range of oncogenic clients, including diverse kinases, transcription factors and oncogenic fusion proteins. Therefore, it could be...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/16/2556 |
| _version_ | 1827628811687034880 |
|---|---|
| author | Xiude Ren Tao Li Wei Zhang Xuejun Yang |
| author_facet | Xiude Ren Tao Li Wei Zhang Xuejun Yang |
| author_sort | Xiude Ren |
| collection | DOAJ |
| description | Heat-shock protein 90 (HSP90) is an important molecule chaperone associated with tumorigenesis and malignancy. HSP90 is involved in the folding and maturation of a wide range of oncogenic clients, including diverse kinases, transcription factors and oncogenic fusion proteins. Therefore, it could be argued that HSP90 facilitates the malignant behaviors of cancer cells, such as uncontrolled proliferation, chemo/radiotherapy resistance and immune evasion. The extensive associations between HSP90 and tumorigenesis indicate substantial therapeutic potential, and many HSP90 inhibitors have been developed. However, due to HSP90 inhibitor toxicity and limited efficiency, none have been approved for clinical use as single agents. Recent results suggest that combining HSP90 inhibitors with other anticancer therapies might be a more advisable strategy. This review illustrates the role of HSP90 in cancer biology and discusses the therapeutic value of Hsp90 inhibitors as complements to current anticancer therapies. |
| first_indexed | 2024-03-09T13:40:59Z |
| format | Article |
| id | doaj.art-0c4d22f54dd2421aae710477b55efb66 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T13:40:59Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-0c4d22f54dd2421aae710477b55efb662023-11-30T21:06:52ZengMDPI AGCells2073-44092022-08-011116255610.3390/cells11162556Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination TherapyXiude Ren0Tao Li1Wei Zhang2Xuejun Yang3Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartments of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USADepartment of Neurosurgery, Tsinghua University Beijing Tsinghua Changgung Hospital, Beijing 102218, ChinaHeat-shock protein 90 (HSP90) is an important molecule chaperone associated with tumorigenesis and malignancy. HSP90 is involved in the folding and maturation of a wide range of oncogenic clients, including diverse kinases, transcription factors and oncogenic fusion proteins. Therefore, it could be argued that HSP90 facilitates the malignant behaviors of cancer cells, such as uncontrolled proliferation, chemo/radiotherapy resistance and immune evasion. The extensive associations between HSP90 and tumorigenesis indicate substantial therapeutic potential, and many HSP90 inhibitors have been developed. However, due to HSP90 inhibitor toxicity and limited efficiency, none have been approved for clinical use as single agents. Recent results suggest that combining HSP90 inhibitors with other anticancer therapies might be a more advisable strategy. This review illustrates the role of HSP90 in cancer biology and discusses the therapeutic value of Hsp90 inhibitors as complements to current anticancer therapies.https://www.mdpi.com/2073-4409/11/16/2556heat-shock protein 90 inhibitorsmolecular chaperonesHSP90cancer therapycombinational therapy |
| spellingShingle | Xiude Ren Tao Li Wei Zhang Xuejun Yang Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy Cells heat-shock protein 90 inhibitors molecular chaperones HSP90 cancer therapy combinational therapy |
| title | Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy |
| title_full | Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy |
| title_fullStr | Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy |
| title_full_unstemmed | Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy |
| title_short | Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy |
| title_sort | targeting heat shock protein 90 in cancer an update on combination therapy |
| topic | heat-shock protein 90 inhibitors molecular chaperones HSP90 cancer therapy combinational therapy |
| url | https://www.mdpi.com/2073-4409/11/16/2556 |
| work_keys_str_mv | AT xiuderen targetingheatshockprotein90incanceranupdateoncombinationtherapy AT taoli targetingheatshockprotein90incanceranupdateoncombinationtherapy AT weizhang targetingheatshockprotein90incanceranupdateoncombinationtherapy AT xuejunyang targetingheatshockprotein90incanceranupdateoncombinationtherapy |